PPIDT00349
Drug Information
| Name | Ibalizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB12698 |
| Type | biotech |
| Indication | Indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in highly treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen [FDA label]. The approval of Trogarzo was supported by a clinical trial of 40 treatment-experienced adults with MDR HIV-1 infection who persistently had elevated levels of HIV RNA in their blood despite heavy antiretroviral therapy. The majority of study patients had previously been treated with ≥10 antiretroviral medications [L1554]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
150 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
200 MG
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P51681 | CCR5 | C-C chemokine receptor type 5 | Homo sapiens | antagonist | Link |
| target | P61073 | CXCR4 | C-X-C chemokine receptor type 4 | Homo sapiens | antagonist | Link |
| target | P01730 | CD4 | T-cell surface glycoprotein CD4 | Homo sapiens | antagonist | Link |